1
|
Bagit A, Maliyar K, Mansour M, Georgakopoulos JR, Rankin B, Lytvyn Y, Zaaroura H, Park YJ, Wang E, Mufti A, Torres T, Le AM, Vender R, Prajapati VH, Yeung J. Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 1-year International Multicenter Retrospective Cohort Study. J Am Acad Dermatol 2024:S0190-9622(24)00654-6. [PMID: 38677338 DOI: 10.1016/j.jaad.2024.03.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2024] [Accepted: 03/23/2024] [Indexed: 04/29/2024]
Affiliation(s)
- A Bagit
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - K Maliyar
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - M Mansour
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - J R Georgakopoulos
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - B Rankin
- Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Y Lytvyn
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - H Zaaroura
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Y J Park
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - E Wang
- Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - A Mufti
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
| | - T Torres
- Department of Dermatology, Centro Hospitalar de Santo António, 4099-001 Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, 4050-313 Porto, Portugal
| | - A M Le
- Department of Dermatology, Centro Hospitalar de Santo António, 4099-001 Porto, Portugal
| | - R Vender
- Dermatrials Research Inc. and Venderm Consulting, Hamilton, Ontario, Canada
| | - V H Prajapati
- Division of Dermatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Section of Community Pediatrics, University of Calgary, Calgary, Alberta, Canada; Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada
| | - J Yeung
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; Probity Medical Research, Toronto, Ontario, Canada.
| |
Collapse
|
2
|
Luz M, Lé AM, Torres T. Risankizumab in the Management of Psoriasis in Solid Organ Transplant Recipients. Actas Dermosifiliogr 2024:S0001-7310(24)00054-1. [PMID: 38307168 DOI: 10.1016/j.ad.2023.09.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 09/02/2023] [Accepted: 09/14/2023] [Indexed: 02/04/2024] Open
Affiliation(s)
- M Luz
- Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - A M Lé
- Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
| |
Collapse
|
3
|
Noujarède J, Carrié L, Garcia V, Grimont M, Eberhardt A, Mucher E, Genais M, Schreuder A, Carpentier S, Ségui B, Nieto L, Levade T, Puig S, Torres T, Malvehy J, Harou O, Lopez J, Dalle S, Caramel J, Gibot L, Riond J, Andrieu-Abadie N. Sphingolipid paracrine signaling impairs keratinocyte adhesion to promote melanoma invasion. Cell Rep 2023; 42:113586. [PMID: 38113139 DOI: 10.1016/j.celrep.2023.113586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Revised: 10/20/2023] [Accepted: 11/30/2023] [Indexed: 12/21/2023] Open
Abstract
Melanoma is the deadliest form of skin cancer due to its propensity to metastasize. It arises from melanocytes, which are attached to keratinocytes within the basal epidermis. Here, we hypothesize that, in addition to melanocyte-intrinsic modifications, dysregulation of keratinocyte functions could initiate early-stage melanoma cell invasion. We identified the lysolipid sphingosine 1-phosphate (S1P) as a tumor paracrine signal from melanoma cells that modifies the keratinocyte transcriptome and reduces their adhesive properties, leading to tumor invasion. Mechanistically, tumor cell-derived S1P reduced E-cadherin expression in keratinocytes via S1P receptor dependent Snail and Slug activation. All of these effects were blocked by S1P2/3 antagonists. Importantly, we showed that epidermal E-cadherin expression was inversely correlated with the expression of the S1P-producing enzyme in neighboring tumors and the Breslow thickness in patients with early-stage melanoma. These findings support the notion that E-cadherin loss in the epidermis initiates the metastatic cascade in melanoma.
Collapse
Affiliation(s)
- Justine Noujarède
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Lorry Carrié
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Virginie Garcia
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Maxime Grimont
- Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre de Recherches en Cancérologie de Lyon, Lyon, France
| | - Anaïs Eberhardt
- Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre de Recherches en Cancérologie de Lyon, Lyon, France; Service de Dermatologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Elodie Mucher
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Matthieu Genais
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Anne Schreuder
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Stéphane Carpentier
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Bruno Ségui
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Laurence Nieto
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Thierry Levade
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France; Laboratoire de Biochimie Métabolique, CHU de Toulouse, Toulouse, France
| | - Susana Puig
- Melanoma Unit, Department of Dermatology, University of Barcelona, Barcelona, Spain & CIBER of Rare Diseases, Instituto de Salud Carlos III, Barcelona, Spain
| | - Teresa Torres
- Melanoma Unit, Department of Dermatology, University of Barcelona, Barcelona, Spain & CIBER of Rare Diseases, Instituto de Salud Carlos III, Barcelona, Spain
| | - Josep Malvehy
- Melanoma Unit, Department of Dermatology, University of Barcelona, Barcelona, Spain & CIBER of Rare Diseases, Instituto de Salud Carlos III, Barcelona, Spain
| | - Olivier Harou
- Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre de Recherches en Cancérologie de Lyon, Lyon, France; Service de Dermatologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Jonathan Lopez
- Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre de Recherches en Cancérologie de Lyon, Lyon, France; Service de Dermatologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Stéphane Dalle
- Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre de Recherches en Cancérologie de Lyon, Lyon, France; Service de Dermatologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Julie Caramel
- Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre de Recherches en Cancérologie de Lyon, Lyon, France
| | - Laure Gibot
- Université Toulouse III Paul-Sabatier, Laboratoire des Interactions Moléculaires et Réactivité Chimique et Photochimique, CNRS UMR5623, Toulouse, France
| | - Joëlle Riond
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | - Nathalie Andrieu-Abadie
- Université de Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France.
| |
Collapse
|
4
|
Reymundo A, Armesto S, Rodríguez L, Baniandrés O, Sahuquillo-Torralba A, Torres T, de la Cueva P, Llamas-Velasco M, Daudén E. Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice. J Eur Acad Dermatol Venereol 2023; 37:e1480-e1482. [PMID: 37471473 DOI: 10.1111/jdv.19371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2022] [Accepted: 07/18/2023] [Indexed: 07/22/2023]
Affiliation(s)
- A Reymundo
- Dermatology Department, Hospital universitario de la Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain
| | - S Armesto
- Dermatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - L Rodríguez
- Dermatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - O Baniandrés
- Dermatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - T Torres
- Dermatology Department, Centro Hospitalar e Universitario do Porto, Porto, Portugal
| | - P de la Cueva
- Dermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - M Llamas-Velasco
- Dermatology Department, Hospital universitario de la Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain
| | - E Daudén
- Dermatology Department, Hospital universitario de la Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain
| |
Collapse
|
5
|
Alvarenga JM, Maria Lé A, Torres T. Dupilumab for Atopic Dermatitis During Pregnancy and Breastfeeding: A Case Report. Actas Dermosifiliogr 2023:S0001-7310(23)00817-7. [PMID: 37858861 DOI: 10.1016/j.ad.2023.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 09/12/2023] [Accepted: 10/12/2023] [Indexed: 10/21/2023] Open
Affiliation(s)
- J M Alvarenga
- Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - A Maria Lé
- Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário de Santo António, Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
| |
Collapse
|
6
|
Skrek S, Di Lernia V, Beauchet A, Bursztejn AC, Belloni Fortina A, Lesiak A, Thomas J, Brzezinski P, Topkarci Z, Murashkin N, Torres T, Epishev R, Chiriac A, McPherson T, Akinde M, Maruani A, Luna PC, Vidaurri de la Cruz H, Mallet S, Leducq S, Sergeant M, Zitouni J, Mahil SK, Smith CH, Flohr C, Bachelez H, Mahé E. Clinical and epidemiological features of psoriasis exacerbations in children with SARS-CoV-2 infection. J Eur Acad Dermatol Venereol 2023; 37:e1192-e1195. [PMID: 37326146 DOI: 10.1111/jdv.19261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Accepted: 06/13/2023] [Indexed: 06/17/2023]
Affiliation(s)
- S Skrek
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - V Di Lernia
- Dermatology Unit, Arcispedale S. Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - A Beauchet
- Department of Public Health, Hôpital Raymond Poincaré, Garches, France
| | - A-C Bursztejn
- Department of Dermatology, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - A Belloni Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
| | - A Lesiak
- Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
| | - J Thomas
- J. T. Skin Care Centre, Chennai, India
| | - P Brzezinski
- Department of Dermatology, Voivodship Specialist Hospital in Slupsk, Slupsk, Poland
| | - Z Topkarci
- Department of Dermatology, Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
| | - N Murashkin
- Department of Dermatology, Federal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - R Epishev
- Department of Dermatology, Federal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian Federation, Moscow, Russia
| | - A Chiriac
- Department of Dermatology, Nicolina Medical Center, P. Poni Institute of Macromolecular Chemistry, Romanian Academy, Iași, Romania
| | - T McPherson
- Department of Dermatology, Oxford University Hospitals NHS Trust, Oxford, UK
| | - M Akinde
- Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - A Maruani
- Unit of Pediatric Dermatology, Department of Dermatology, University of Tours and Nantes, INSERM 1246 SPHERE - CHRU Tours, Tours, France
| | - P C Luna
- Department of Dermatology, Hospital Alemán, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - H Vidaurri de la Cruz
- Servicio de Dermatología Pediátrica, Hospital General de México Dr. Eduardo Liceaga, Secretaría de Salud, Ciudad de México, Mexico
| | - S Mallet
- Department of Dermatology, Hôpital de la Timone, Assistance-Publique-Hôpitaux de Marseille, Marseille, France
| | - S Leducq
- Unit of Pediatric Dermatology, Department of Dermatology, University of Tours and Nantes, INSERM 1246 SPHERE - CHRU Tours, Tours, France
| | - M Sergeant
- Department of Dermatology, Hôpitaux de Brabois, Centre Hospitalier Universitaire de Nancy, Vandœuvre-lès-Nancy, France
| | - J Zitouni
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| | - S K Mahil
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - C H Smith
- Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - C Flohr
- Department of Dermatology, Oxford University Hospitals NHS Trust, Oxford, UK
| | - H Bachelez
- Department of Dermatology, Hôpital Saint-Louis, AP-HP, Paris, France
- Laboratory of Genetic Skin Diseases, INSERM U1163, Imagine Institute, Université de Paris, Paris, France
| | - E Mahé
- Department of Dermatology, Hôpital Victor Dupouy, Argenteuil, France
| |
Collapse
|
7
|
Reich A, Pinter A, Maul JT, Vender RB, Torres T, Brnabic A, Haustrup N, Reed C, Schuster C, Riedl E. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. J Eur Acad Dermatol Venereol 2023; 37:1825-1840. [PMID: 37147855 DOI: 10.1111/jdv.19161] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 04/24/2023] [Indexed: 05/07/2023]
Abstract
BACKGROUND Rapid skin improvement is a key treatment goal of patients with moderate-to-severe psoriasis (PsO). OBJECTIVES To compare the speed of clinical improvement of approved biologics on the symptoms and signs of psoriasis assessed by patients using the validated Psoriasis Symptoms and Signs Diary (PSSD) through 12 weeks. METHODS Psoriasis Study of Health Outcomes (PSoHO) is an international, prospective, non-interventional study that compares the effectiveness of anti-interleukin (IL)-17A biologics versus other biologics, together with pairwise comparisons of ixekizumab versus five individual biologics in patients with PsO. Using the PSSD 7-day recall period, patients assessed the symptoms (itch, skin tightness, burning, stinging and pain) and signs (dryness, cracking, scaling, shedding/flaking, redness and bleeding) of their psoriasis (0-10). Symptom and sign summary scores (0-100) are derived from the average of individual scores. Percentage change in summary scores and proportion of patients with clinically meaningful improvements (CMI) in PSSD summary and individual scores are evaluated weekly. Longitudinal PSSD data are reported as observed with treatment comparisons analysed using mixed model for repeated measures (MMRM) and generalized linear mixed models (GLMM). RESULTS Across cohorts and treatments, eligible patients (n = 1654) had comparable baseline PSSD scores. From Week 1, the anti-IL-17A cohort achieved significantly larger score improvements in PSSD summary scores and a higher proportion of patients showed CMIs compared to the other biologics cohort through 12 weeks. Lower PSSD scores were associated with a greater proportion of patients reporting their psoriasis as no longer impacting their quality-of-life (DLQI 0,1) and a high level of clinical response (PASI100). Results also indicate a relationship between an early CMI in PSSD score at Week 2 and PASI100 score at Week 12. CONCLUSIONS Treatment with anti-IL-17A biologics, particularly ixekizumab, resulted in rapid and sustained patient-reported improvements in psoriasis symptoms and signs compared with other biologics in a real-world setting.
Collapse
Affiliation(s)
- A Reich
- Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
| | - A Pinter
- Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - J-T Maul
- Department of Dermatology and Venereology, University Hospital of Zürich and Faculty of Medicine, University of Zürich, Zürich, Switzerland
| | - R B Vender
- Dermatrials Research Inc. and Venderm Consulting, Hamilton, Ontario, Canada
| | - T Torres
- Department of Dermatology and Dermatology Research Unit, Centro Hospitalar Universitário do Porto, University of Porto, Porto, Portugal
| | - A Brnabic
- Eli Lilly and Company, Indiana, Indianapolis, USA
| | - N Haustrup
- Eli Lilly and Company, Indiana, Indianapolis, USA
| | - C Reed
- Eli Lilly and Company, Indiana, Indianapolis, USA
| | - C Schuster
- Eli Lilly and Company, Indiana, Indianapolis, USA
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - E Riedl
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| |
Collapse
|
8
|
Chiricozzi A, Ferrucci SM, Di Nardo L, Gori N, Balato A, Ortoncelli M, Maurelli M, Galluzzo M, Munera Campos M, Seremet T, Caldarola G, De Simone C, Ippoliti E, Torres T, Gkalpakiotis S, Conrad C, Carrascosa JM, Bianchi L, Argenziano G, Ribero S, Girolomoni G, Marzano AV, Peris K. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study. Expert Opin Biol Ther 2023; 23:1307-1315. [PMID: 38108300 DOI: 10.1080/14712598.2023.2292627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 12/05/2023] [Indexed: 12/19/2023]
Abstract
BACKGROUND Tralokinumab is a human monoclonal antibody targeting interleukin-13 that is approved for the treatment of moderate-severe atopic dermatitis. Studies analyzing the efficacy and safety of tralokinumab in a real-world setting are scarce. RESEARCH DESIGN AND METHODS A European, multicentric, real-world, retrospective cohort study was defined to assess the effectiveness and safeness profile of tralokinumab, investigating the achievement of pre-specified treatment goals; and to detect potential differences in terms of effectiveness and safeness across some selected patient subcohorts. RESULTS A total of 194 adult patients were included in this study. A significant improvement in physician-assessed disease severity was detected at each follow-up visit as compared with baseline and similar trend was observed for patient-reported outcomes and quality of life. No meaningful difference in effectiveness was found when considering patient age (<65 versus ≥65 years), neither dissecting patient cohort in dupilumab-naive vs dupilumab-treated subjects. Among tralokinumab-treated patients, 88% achieved at least one currently identified real-world therapeutic goal at week 16. CONCLUSIONS This retrospective multicenter study confirmed the effectiveness and safeness of tralokinumab throughout 32 weeks of observation, showing the achievement of therapeutic goals identified in both trial and real-world settings in a large proportion of tralokinumab-treated patients.
Collapse
Affiliation(s)
- A Chiricozzi
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - S M Ferrucci
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - L Di Nardo
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - N Gori
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A Balato
- Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy
| | - M Ortoncelli
- Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - M Maurelli
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - M Galluzzo
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy
- Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy
| | - M Munera Campos
- Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain
| | - T Seremet
- Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
| | - G Caldarola
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - C De Simone
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - E Ippoliti
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário de Santo António, University of Porto, Porto, Portugal
| | - S Gkalpakiotis
- Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic
| | - C Conrad
- Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, Switzerland
| | - J M Carrascosa
- Department of Dermatology, Germans Trias i Pujol University Hospital (HUGTP), Autonomous University of Barcelona (UAB), Badalona, Spain
| | - L Bianchi
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy
- Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy
| | - G Argenziano
- Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy
| | - S Ribero
- Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy
| | - G Girolomoni
- Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
| | - A V Marzano
- Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy
| | - K Peris
- Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| |
Collapse
|
9
|
Fosse V, Oldoni E, Bietrix F, Budillon A, Daskalopoulos EP, Fratelli M, Gerlach B, Groenen PMA, Hölter SM, Menon JML, Mobasheri A, Osborne N, Ritskes-Hoitinga M, Ryll B, Schmitt E, Ussi A, Andreu AL, McCormack E, Demotes J, Garcia P, Gerardi C, Glaab E, Haro JM, Hulstaert F, Miguel LS, Mirete JS, Niubo AS, Porcher R, Rauschenberger A, Rodriguez MC, Superchi C, Torres T. Recommendations for robust and reproducible preclinical research in personalised medicine. BMC Med 2023; 21:14. [PMID: 36617553 PMCID: PMC9826728 DOI: 10.1186/s12916-022-02719-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Accepted: 12/19/2022] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND Personalised medicine is a medical model that aims to provide tailor-made prevention and treatment strategies for defined groups of individuals. The concept brings new challenges to the translational step, both in clinical relevance and validity of models. We have developed a set of recommendations aimed at improving the robustness of preclinical methods in translational research for personalised medicine. METHODS These recommendations have been developed following four main steps: (1) a scoping review of the literature with a gap analysis, (2) working sessions with a wide range of experts in the field, (3) a consensus workshop, and (4) preparation of the final set of recommendations. RESULTS Despite the progress in developing innovative and complex preclinical model systems, to date there are fundamental deficits in translational methods that prevent the further development of personalised medicine. The literature review highlighted five main gaps, relating to the relevance of experimental models, quality assessment practices, reporting, regulation, and a gap between preclinical and clinical research. We identified five points of focus for the recommendations, based on the consensus reached during the consultation meetings: (1) clinically relevant translational research, (2) robust model development, (3) transparency and education, (4) revised regulation, and (5) interaction with clinical research and patient engagement. Here, we present a set of 15 recommendations aimed at improving the robustness of preclinical methods in translational research for personalised medicine. CONCLUSIONS Appropriate preclinical models should be an integral contributor to interventional clinical trial success rates, and predictive translational models are a fundamental requirement to realise the dream of personalised medicine. The implementation of these guidelines is ambitious, and it is only through the active involvement of all relevant stakeholders in this field that we will be able to make an impact and effectuate a change which will facilitate improved translation of personalised medicine in the future.
Collapse
Affiliation(s)
- Vibeke Fosse
- Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.
| | - Emanuela Oldoni
- EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam, The Netherlands
| | - Florence Bietrix
- EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam, The Netherlands
| | - Alfredo Budillon
- Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy
| | | | - Maddalena Fratelli
- Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Björn Gerlach
- PAASP GmbH, Guarantors of EQIPD e.V., Central Institute for Mental Health in Mannheim, Mannheim, Germany
| | | | | | - Julia M L Menon
- Preclinicaltrials.eu, Netherlands Heart Institute, Utrecht, The Netherlands
| | - Ali Mobasheri
- Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, 90570, Oulu, Finland.,Department of Regenerative Medicine, State Research Institute Centre for Innovative Medicine, LT-08406, Vilnius, Lithuania.,Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.,Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, 508, GA, Utrecht, The Netherlands.,World Health Organization Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Université de Liège, B-4000, Liège, Belgium
| | | | - Merel Ritskes-Hoitinga
- Department of Population Health Sciences, IRAS, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.,Department of Clinical Medicine, AUGUST, Aarhus University, Aarhus, Denmark
| | - Bettina Ryll
- Melanoma Patient Network Europe, Uppsala, Sweden
| | - Elmar Schmitt
- Global Regulatory Oncology, Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany
| | - Anton Ussi
- EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam, The Netherlands
| | - Antonio L Andreu
- EATRIS ERIC, European Infrastructure for Translational Medicine, Amsterdam, The Netherlands
| | - Emmet McCormack
- Department of Clinical Science, Centre for Cancer Biomarkers, University of Bergen, Bergen, Norway.,Department of Clinical Science, Centre for Pharmacy, The University of Bergen, Bergen, Norway
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Elias-Mas A, Potrony M, Bague J, Cutler DJ, Alvarez-Mora MI, Torres T, Barcos T, Puig-Butille JA, Rubio M, Madrigal I, Puig S, Allen EG, Rodriguez-Revenga L. Evaluation of AQP4 functional variants and its association with fragile X-associated tremor/ataxia syndrome. Front Aging Neurosci 2023; 14:1073258. [PMID: 36688175 PMCID: PMC9853890 DOI: 10.3389/fnagi.2022.1073258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 12/19/2022] [Indexed: 01/07/2023] Open
Abstract
Introduction Fragile X-associated tremor/ataxia syndrome (FXTAS, OMIM# 300623) is a late-onset neurodegenerative disorder with reduced penetrance that appears in adult FMR1 premutation carriers (55-200 CGGs). Clinical symptoms in FXTAS patients usually begin with an action tremor. After that, different findings including ataxia, and more variably, loss of sensation in the distal lower extremities and autonomic dysfunction, may occur, and gradually progress. Cognitive deficits are also observed, and include memory problems and executive function deficits, with a gradual progression to dementia in some individuals. Aquaporin 4 (AQP4) is a commonly distributed water channel in astrocytes of the central nervous system. Changes in AQP4 activity and expression have been implicated in several central nervous system disorders. Previous studies have suggested the associations of AQP4 single nucleotide polymorphisms (SNPs) with brain-water homeostasis, and neurodegeneration disease. To date, this association has not been studied in FXTAS. Methods To investigate the association of AQP4 SNPs with the risk of presenting FXTAS, a total of seven common AQP4 SNPs were selected and genotyped in 95 FMR1 premutation carriers with FXTAS and in 65 FMR1 premutation carriers without FXTAS. Results The frequency of AQP4-haplotype was compared between groups, denoting 26 heterozygous individuals and 5 homozygotes as carriers of the minor allele in the FXTAS group and 25 heterozygous and 2 homozygotes in the no-FXTAS group. Statistical analyses showed no significant associations between AQP4 SNPs/haplotypes and development of FXTAS. Discussion Although AQP4 has been implicated in a wide range of brain disorders, its involvement in FXTAS remains unclear. The identification of novel genetic markers predisposing to FXTAS or modulating disease progression is critical for future research involving predictors and treatments.
Collapse
Affiliation(s)
- Andrea Elias-Mas
- Radiology Department, Hospital Universitari Mútua de Terrassa, Terrassa, Barcelona, Spain
- Institute for Research and Innovation Parc Taulí (I3PT), Sabadell, Spain
- Genetics Doctorate Program, Universitat de Barcelona (UB), Barcelona, Spain
| | - Miriam Potrony
- Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| | - Jaume Bague
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - David J. Cutler
- Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, United States
| | - Maria Isabel Alvarez-Mora
- Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| | - Teresa Torres
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| | - Tamara Barcos
- Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Joan Anton Puig-Butille
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
- Molecular Biology CORE, Hospital Clinic of Barcelona, Barcelona, Spain
| | - Marta Rubio
- Institute for Research and Innovation Parc Taulí (I3PT), Sabadell, Spain
- Department of Neurology, Parc Taulí Hospital Universitari, Sabadell, Spain
| | - Irene Madrigal
- Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| | - Susana Puig
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
- Dermatology Department, Melanoma Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain
| | - Emily G. Allen
- Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, United States
| | - Laia Rodriguez-Revenga
- Biochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| |
Collapse
|
11
|
Zitouni J, Bursztejn A, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, Mcpherson T, Akinde M, Maruani A, Epishev R, Vidaurri De La Cruz H, Luna P, Amy De La Breteque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, Van Den Reek J, Sonkoly E, Kupfer-Bessaguet I, Leducq S, Mahil S, Smith C, Flohr C, Bachelez H, Mahé E. COVID-19 et psoriasis de l’enfant : facteurs associés à une évolution défavorable de la COVID-19 et impact de l’infection sur le psoriasis. Registre Chi-PsoCov. Annales de Dermatologie et de Vénéréologie - FMC 2022. [PMCID: PMC9748132 DOI: 10.1016/j.fander.2022.09.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
12
|
Rodriguez E, Olazagasti C, Khan K, Kareff S, Torres T, Torrents S, Fernandez-Vega Martinez G, MacIntyre J, Lopes G. EP04.01-010 Addressing Barriers to Lung Cancer Care for Diverse Populations through Patient Navigation: The University of Miami Experience. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
13
|
Zitouni J, Bursztejn A, Belloni Fortina A, Beauchet A, Di Lernia V, Lesiak A, Thomas J, Topkarci Z, Murashkin N, Brzezinski P, Torres T, Chiriac A, Luca C, McPherson T, Akinde M, Maruani A, Epishev R, Vidaurri de la Cruz H, Luna P, Amy de la Bretêque M, Lasek A, Bourrat E, Bachelerie M, Mallet S, Steff M, Bellissen A, Neri I, Zafiriou E, van den Reek J, Sonkoly E, Mahil S, Smith C, Flohr C, Bachelez H, Mahé E. Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). J Eur Acad Dermatol Venereol 2022; 36:2076-2086. [PMID: 35748102 PMCID: PMC9349726 DOI: 10.1111/jdv.18361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 06/10/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. OBJECTIVES The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. METHODS We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. RESULTS One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). DISCUSSION Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.
Collapse
Affiliation(s)
- J. Zitouni
- Department of DermatologyHôpital Victor DupouyArgenteuilFrance
| | - A.‐C. Bursztejn
- Department of DermatologyHôpitaux de Brabois, Centre Hospitalier Universitaire de NancyVandœuvre‐lès‐NancyFrance
| | - A. Belloni Fortina
- Pediatric Dermatology Unit, Department of Medicine DIMEDUniversity of PadovaPadovaItaly
| | - A. Beauchet
- Department of Public HealthHôpital Ambroise ParéBoulogne‐BillancourtFrance
| | - V. Di Lernia
- Dermatology UnitArcispedale S. Maria Nuova, Azienda USL‐IRCCS di Reggio EmiliaReggio EmiliaItaly
| | - A. Lesiak
- Department of Dermatology, Peadiatric Dermatology and OncologyMedical Univeristy of LodzLodzPoland
| | - J. Thomas
- J. T. Skin Care CentreChennaiTamil NaduIndia
| | - Z. Topkarci
- Department of DermatologyDr. Sadi Konuk Training and Research HospitalIstanbulTurkey
| | - N. Murashkin
- Department of DermatologyFederal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian FederationMoscowRussia
| | - P. Brzezinski
- Department of DermatologyVoivodship Specialist Hospital in SlupskUstkaPoland
| | - T. Torres
- Department of DermatologyCentro Hospitalar Universitário do PortoPortoPortugal
| | - A. Chiriac
- Department of Dermatology, Nicolina Medical CenterP. Poni Institute of Macromolecular Chemistry, Romanian AcademyIașiRomania
| | - C. Luca
- Infectious Disease Department, “Sf. Parascheva” Clinical Hospital“Gr. T. Popa” University of MedicineIasiRomania
| | - T. McPherson
- Department of DermatologyOxford University Hospitals NHS TrustOxfordUK
| | - M. Akinde
- Department of Paediatric Dermatology, St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation TrustLondonUK
| | - A. Maruani
- Unit of Pediatric Dermatology, Department of DermatologyUniversity of Tours and Nantes, INSERM 1246 SPHERE ‐ CHRU ToursToursFrance
| | - R. Epishev
- Department of DermatologyFederal State Autonomous Institution, Scientific Center of Children's Health of the Ministry of Health of the Russian FederationMoscowRussia
| | - H. Vidaurri de la Cruz
- Servicio de Dermatología PediátricaHospital General de México Dr. Eduardo Liceaga, Secretaría de SaludCiudad de MéxicoMexico
| | - P.C. Luna
- Department of DermatologyHospital AlemánCiudad Autónoma de Buenos AiresArgentina
| | | | - A. Lasek
- Department of Dermatology, Hôpital Saint Vincent de PaulUniversité Catholique de LilleLilleFrance
| | - E. Bourrat
- Department of DermatologyHôpital Robert Debré, AP‐HPParisFrance
| | - M. Bachelerie
- Department of DermatologyCentre Hospitalier UniversitaireClermont‐FerrandFrance
| | - S. Mallet
- Department of Dermatology, Hôpital de la TimoneAssistance‐publique‐Hôpitaux de MarseilleMarseilleFrance
| | - M. Steff
- Department of DermatologyCentre Hospitalier Intercommunal Robert BallangerAulnay‐sous‐BoisFrance
| | - A. Bellissen
- Department of DermatologyCentre Hospitalier Edmond GarcinAubagneFrance
| | - I. Neri
- Department of DermatologyIRCSS Azienda Ospedaliero Universitaria di BolognaBolognaItaly
| | - E. Zafiriou
- Department of Dermatology, Faculty of Medicine, School of Health SciencesUniversity of ThessalyLarissaGreece
| | | | - E. Sonkoly
- Dermatology and Venereology Division, Department of Medicine SolnaKarolinska InstitutetStockholmSweden,Center for Molecular Medicine (CMM)Karolinska InstitutetStockholmSweden,Dermatology, Department of Medical SciencesUppsala UniversityUppsalaSweden
| | - S.K. Mahil
- St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation Trust and King's College LondonLondonUK
| | - C.H. Smith
- St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation Trust and King's College LondonLondonUK
| | - C. Flohr
- Department of Paediatric Dermatology, St John's Institute of DermatologyGuy's and St Thomas' NHS Foundation TrustLondonUK
| | - H. Bachelez
- Department of DermatologyHôpital Saint‐Louis, AP‐HPParisFrance,Laboratory of Genetic Skin Diseases, INSERM U1163, Imagine InstituteUniversité de ParisParisFrance
| | - E. Mahé
- Department of DermatologyHôpital Victor DupouyArgenteuilFrance
| | | |
Collapse
|
14
|
Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, Ghislain PD, Torres T, Ioannides D, Aassi M, Schulz B, Jagiello P. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate to severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol 2022; 36:1796-1804. [PMID: 35696305 DOI: 10.1111/jdv.18329] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 04/29/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND Randomised controlled trials of secukinumab have shown sustained efficacy and a favourable safety profile in multiple manifestations of psoriatic disease. OBJECTIVES To assess the long-term, real-world retention, effectiveness, and safety of secukinumab in routine clinical practice for the treatment of moderate to severe plaque-type psoriasis (PsO). METHODS SERENA (CAIN457A3403) is a large, ongoing, longitudinal, observational study conducted at 438 sites and 19 countries across Europe for an expected duration of up to 5 years in adult patients with moderate to severe PsO, psoriatic arthritis, and ankylosing spondylitis. Patients received ≥16 weeks of secukinumab treatment before enrolment. This interim analysis presents data from PsO patients, who were enrolled in the study between October-2016-October-2018 and were observed for ≥2 years. RESULTS In total, 1756 patients (67.3% male) with a mean age of 48.4 years and body mass index of 28.8 kg/m2 were included in the analysis. The secukinumab treatment retention rates after 1, 2 and 3 years in the study were 88.0%, 76.4% and 60.5%, respectively. Out of the 648 patients who discontinued the study, the most common reasons included lack of efficacy (42.6%), adverse event (17.4%), physician decision (12.2%) and subject decision (11.6%). Mean±SD absolute PASI was 21.0±13.0 at the start of treatment (n=1,564). At Baseline, the mean±SD PASI score reduced to 2.6±4.8 and remained low at Year 1 (2.3±4.3), Year 2 (1.9±3.6) and Year 3 (1.9±3.5). The safety profile of secukinumab during the SERENA study was consistent with its known safety profile, with no new safety signals reported. Particularly low rates of inflammatory bowel disease (0.3%; Incidence Rate [IR]:0.15), candida infections (3.1%; IR:1.43) and MACE (0.9%; IR:0.37) were observed. CONCLUSIONS Secukinumab showed high treatment persistence, sustained effectiveness and a favourable safety profile up to 3 years of follow-up in the real-world population of PsO patients observed in SERENA.
Collapse
Affiliation(s)
- M Augustin
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P G Sator
- Department of Dermatology, Municipal Hospital Hietzing, Vienna, Austria
| | - R von Kiedrowski
- Company for Medical Study & Service Selters (CMS3) GmbH, Selters, Germany
| | - C Conrad
- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
| | - D Rigopoulos
- Dermatology and Venerology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
| | - M Romanelli
- Dermatology Department, University of Pisa, Pisa, Italy
| | - P-D Ghislain
- Dermatology, Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - D Ioannides
- First Department of Dermatology and Venereology, School of Medicine, Aristotle University, Thessaloniki, Greece
| | - M Aassi
- Novartis Pharma AG, Basel, Switzerland
| | - B Schulz
- Novartis Pharma AG, Basel, Switzerland
| | | | | |
Collapse
|
15
|
Reolid A, Armesto S, Sahuquillo-Torralba A, Torres T, Feltes R, Vilarrasa E, Belinchón I, de la Cueva P, Rodríguez L, Romero-Maté A, Vidal D, Coto-Segura P, Herrera-Acosta E, Riera-Monroig J, Salgado L, Llamas-Velasco M, Daudén E. Secukinumab is effective and safe in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. J Am Acad Dermatol 2022; 87:705-709. [PMID: 35640798 DOI: 10.1016/j.jaad.2022.05.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 11/24/2022]
Affiliation(s)
- A Reolid
- Hospital Universitario de la Princesa (Madrid, Spain)
| | - S Armesto
- Hospital Universitario Marqués de Valdecilla (Santander, Spain)
| | - A Sahuquillo-Torralba
- Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitária La Fe (Valencia, Spain)
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário do Porto (Porto, Portugal)
| | - R Feltes
- Hospital Universitario la Paz (Madrid, Spain)
| | - E Vilarrasa
- Hospital de la Santa Creu i Sant Pau (Barcelona, Spain)
| | - I Belinchón
- Hospital General Universitario de Alicante - ISABIAL (Alicante, Spain)
| | - P de la Cueva
- Hospital Universitario Infanta Leonor (Madrid, Spain)
| | - L Rodríguez
- Hospital Universitario Virgen del Rocío (Sevilla, Spain)
| | | | - D Vidal
- Hospital de Sant Joan Despí Moisés Broggi (Barcelona, Spain)
| | - P Coto-Segura
- Hospital Vital Alvarez-Buylla de Mieres (Asturias, Spain)
| | | | | | - L Salgado
- Complejo Hospitalario Universitario (Pontevedra, Spain)
| | | | - E Daudén
- Hospital Universitario de la Princesa (Madrid, Spain)
| |
Collapse
|
16
|
López-Belzunce M, Blázquez AM, Sánchez-Palencia Y, Torres T, Ortiz JE. Environmental evidence of Valencia lagoon coastal barrier stabilization from 8500 BP to Present. Climate and eustatic variations. Sci Total Environ 2022; 807:151230. [PMID: 34752867 DOI: 10.1016/j.scitotenv.2021.151230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2020] [Revised: 09/28/2021] [Accepted: 10/22/2021] [Indexed: 06/13/2023]
Abstract
The Albufera de Valencia is one of the largest lagoon in the Spanish Mediterranean. Two continuous borehole cores reaching depths of 8 and 14 m in the northern part of the lagoon underwent sedimentological, micropaleontological and biological study. The organic content was also analysed, and 14C radiometric dating and amino acid racemization were performed. Study of the content of benthic foraminifera and n-alkanes and alkanoic acids in the lagoon sedimentary record identified several periods. The core records showed seven different environments: alluvial; freshwater marsh; brackish marsh; brackish lagoon; brackish lagoon with marine connection, backbarrier flat, and backshore. These environments changed due to eight phases associated with the transgression and regression of the barrier system, which caused the shift from exposed environments as the backshore with washover, to the typical low-energy lagoon and marsh deposition. The paleoenvironmental evolution described above is interpreted as a response to global climate changes. The shift from an alluvial setting to a brackish lagoon is probably related to the late of Early Holocene sea level rise ending at the Holocene Climate Optimum, when the highest sea level was reached. The persistence of the brackish lagoon, with no marine connection, is probably synchronous with dry conditions in the area (Booth et al., 2005) at the time of Bond event 3 (i.e., 4.2 ka) in the North Atlantic region (Bond et al., 2001). Finally, the arrival of large amounts of sediment triggered the accretion of the barrier, also enhancing coastal progradation until the present day. These results allow an evaluation of the impact of anthropic action on the Valencia lagoon, especially since the eighteenth century, and a short- and medium-term projection of the consequences of present-day climate change.
Collapse
Affiliation(s)
- M López-Belzunce
- Environmental and Marine Sciences Research Institute (IMEDMAR-UCV), Catholic University of Valencia, C/ Guillem de Castro 94, 46003 Valencia, Spain
| | - A M Blázquez
- Environmental and Marine Sciences Research Institute (IMEDMAR-UCV), Catholic University of Valencia, C/ Guillem de Castro 94, 46003 Valencia, Spain.
| | - Y Sánchez-Palencia
- Laboratorio de Estratigrafía Biomolecular, E.T.S.I. Minas y Energía de Madrid, Universidad Politécnica de Madrid, C/ Ríos Rosas 21, 28003 Madrid, Spain
| | - T Torres
- Laboratorio de Estratigrafía Biomolecular, E.T.S.I. Minas y Energía de Madrid, Universidad Politécnica de Madrid, C/ Ríos Rosas 21, 28003 Madrid, Spain
| | - J E Ortiz
- Laboratorio de Estratigrafía Biomolecular, E.T.S.I. Minas y Energía de Madrid, Universidad Politécnica de Madrid, C/ Ríos Rosas 21, 28003 Madrid, Spain
| |
Collapse
|
17
|
Torres T, Paiva-Lopes MJ, Gonçalo M, Claro C, Oliveira M, Gomes J, Vieira AP, Amoedo P, Alpalhão M, Nogueira M, Santiago F, Henrique M, Amaro C, Esteves T, Alves J, Cerejeira D, Mendes-Bastos P, Pestana M, Ramos L, Rocha J, Carvalho R, Teixeira L, Selores M, Mota A, Filipe P. Dupilumab for atopic dermatitis: a real-world portuguese multicenter retrospective study. J DERMATOL TREAT 2022; 33:2554-2559. [PMID: 35083945 DOI: 10.1080/09546634.2022.2035309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Introduction: Atopic dermatitis (AD) is a difficult-to-treat inflammatory skin disease with a high impact on patients' quality of life. Dupilumab, an IL-4 and IL-13 inhibitor, was the first monoclonal antibody approved for the treatment of moderate-to-severe AD and is currently approved in patients aged 6 or older.Methods: This is a nationwide, multicenter, retrospective, 48-week study designed by the Portuguese Group of AD to assess real-world efficacy and safety of dupilumab for the treatment of AD.Results: A total of 169 patients were enrolled, with a mean disease duration of 22.75 (±11.98) years. The percentage of patients achieving an improvement of at least 75% in Eczema Area and Severity Index (EASI) compared to baseline (EASI75 response) at weeks 12 and 48 was 67.6% and 74.1%, respectively. In the same timepoints, 25.0% and 44.1% achieved an EASI90 response. Patient-reported outcome measures also improved throughout the study period. Regarding safety, 32.0% of the patients developed adverse events, with conjunctivitis (26.6%), persistent facial erythema (4.7%), and arthritis/arthralgia (3.6%) as the more frequently reported.Conclusion: Data from real-world populations are crucial to guide clinicians in their daily decisions. This study provides data demonstrating that dupilumab is an effective and safe therapeutic option for AD.
Collapse
Affiliation(s)
- T Torres
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.,Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
| | - M J Paiva-Lopes
- Department of Dermatology, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal.,CEDOC, Nova Medical School, Universidade Nova de Lisboa, Lisboa, Portugal
| | - M Gonçalo
- Department of Dermatology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.,Clinic of Dermatology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
| | - C Claro
- Department of Dermatology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal
| | - M Oliveira
- Department of Dermatology, Centro Hospitalar Tondela Viseu, Viseu, Portugal
| | - J Gomes
- Department of Dermatology, Hospital de Braga, Braga, Portugal
| | - A P Vieira
- Department of Dermatology, Hospital de Braga, Braga, Portugal
| | - P Amoedo
- Department of Dermatology, Centro Hospitalar Universitário de São João EPE, Porto, Portugal
| | - M Alpalhão
- Department of Dermatology, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal.,Dermatology University Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.,Dermatology Research Unit, IMM João Lobo Antunes, University of Lisbon, Lisbon, Portugal
| | - M Nogueira
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - F Santiago
- Department of Dermatology, Centro Hospitalar Leiria-Pombal, Leiria, Portugal
| | - M Henrique
- Department of Dermatology, Centro Hospitalar Leiria-Pombal, Leiria, Portugal
| | - C Amaro
- Department of Dermatology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal
| | - T Esteves
- Department of Dermatology, Hospital Central do Funchal, Madeira, Portugal
| | - J Alves
- Department of Dermatology, Hospital Garcia de Orta, Almada, Portugal
| | - D Cerejeira
- Department of Dermatology, Hospital Garcia de Orta, Almada, Portugal
| | - P Mendes-Bastos
- Dermatology Center, Hospital CUF Descobertas, Lisboa, Portugal
| | - M Pestana
- Department of Dermatology, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal
| | - L Ramos
- Department of Dermatology, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal
| | - J Rocha
- Department of Dermatology, Hospital de Pedro Hispano, Matosinhos, Portugal
| | - R Carvalho
- Department of Dermatology, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal.,Nova Medical School, Universidade Nova de Lisboa, Lisboa, Portugal
| | - L Teixeira
- Center for Health Technology and Services Research (CINTESIS), Institute of Biomedical Sciences Abel Salazar, University of Porto (ICBAS.UP), Porto, Portugal
| | - M Selores
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - A Mota
- Department of Dermatology, Centro Hospitalar Universitário de São João EPE, Porto, Portugal.,Faculty of Medicine, University of Porto, CINTESIS, Porto, Portugal
| | - P Filipe
- Department of Dermatology, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal.,Dermatology University Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.,Dermatology Research Unit, IMM João Lobo Antunes, University of Lisbon, Lisbon, Portugal
| | | |
Collapse
|
18
|
Rodrigues M, Freitas E, Torres T. Bimekizumab for psoriasis. Drugs Today (Barc) 2022; 58:273-282. [DOI: 10.1358/dot.2022.58.6.3400572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
19
|
Mahil S, Yates M, Langan S, Yiu Z, Tsakok T, Dand N, Mason K, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce I, Capon F, Contreras C, Cope A, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo‐Ortega H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren R, Waweru H, Weinman J, Griffiths C, Barker J, Brown M, Galloway J, Smith C. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol 2021; 185:80-90. [PMID: 33368145 PMCID: PMC9214088 DOI: 10.1111/bjd.19755] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/19/2020] [Indexed: 01/10/2023]
Abstract
BACKGROUND Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. OBJECTIVES We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. METHODS Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model. RESULTS Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term 'shielding'). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35-1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23-1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05-1·24), obesity (OR 1·37, 95% CI 1·23-1·54), comorbidity burden (OR 1·43, 95% CI 1·15-1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27-1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36-1·80). Modest differences in the proportion shielding were observed across nations. CONCLUSIONS Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk-mitigation strategies and may help inform updated public health guidelines as the pandemic continues.
Collapse
|
20
|
Mahil SK, Yates M, Yiu ZZN, Langan SM, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Capon F, Contreras CR, De La Cruz C, Di Meglio P, Gisondi P, Jullien D, Lambert J, Naldi L, Norton S, Puig L, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Brown MA, Galloway JB, Griffiths CM, Barker JN, Smith CH. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol 2021; 35:e636-e640. [PMID: 34145643 PMCID: PMC8447018 DOI: 10.1111/jdv.17450] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- S K Mahil
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - M Yates
- NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,Centre for Rheumatic Diseases, King's College London, London, UK
| | - Z Z N Yiu
- Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK
| | - S M Langan
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,Faculty of Epidemiology, and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - T Tsakok
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - N Dand
- Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.,Health Data Research UK, London, UK
| | - K J Mason
- Centre for Rheumatic Diseases, King's College London, London, UK.,School of Medicine, Keele University, Keele, UK
| | - H McAteer
- The Psoriasis Association, Northampton, UK
| | - F Meynell
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - B Coker
- NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - A Vincent
- NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - D Urmston
- The Psoriasis Association, Northampton, UK
| | - A Vesty
- The Psoriasis Association, Northampton, UK
| | - J Kelly
- Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK
| | - C Lancelot
- International Federation of Psoriasis Associations (IFPA), Bromma, Sweden
| | - L Moorhead
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | - H Bachelez
- Department of Dermatology, AP-HP Hôpital Saint-Louis, Paris, France.,INSERM U1163, Imagine Institute for Human Genetic Diseases, Université de Paris, Paris, France
| | - F Capon
- NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK
| | - C R Contreras
- Catedra de Dermatologia, Hospital de Clinicas, Facultad de Ciencias Medicas, Universidad Nacional de Asuncion, San Lorenzo, Paraguay
| | | | - P Di Meglio
- NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - P Gisondi
- Section of Dermatology and Venereology, University of Verona, Verona, Italy
| | - D Jullien
- Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France.,Groupe de Recherche sur le Psoriasis (GrPso) de la Société Française de Dermatologie, Paris, France
| | - J Lambert
- Department of Dermatology, Ghent University, Ghent, Belgium
| | - L Naldi
- Centro Studi GISED, Bergamo, Italy
| | - S Norton
- Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - L Puig
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - P Spuls
- Department of Dermatology, Amsterdam Public Health/Infection and Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands
| | - T Torres
- Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal
| | - R B Warren
- Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK
| | - H Waweru
- International Federation of Psoriasis Associations (IFPA), Bromma, Sweden
| | - J Weinman
- School of Cancer and Pharmaceutical Sciences, King's College London, London, UK
| | - M A Brown
- NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,Centre for Rheumatic Diseases, King's College London, London, UK
| | - J B Galloway
- Centre for Rheumatic Diseases, King's College London, London, UK.,Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK
| | - C M Griffiths
- Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, UK
| | - J N Barker
- NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK
| | - C H Smith
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.,NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK
| | | |
Collapse
|
21
|
Rodriguez E, Khan K, Torres T, Dawar R, Gawri K, Ikpeazu C, Lopes G. P36.01 KEAP1 and NRF2 Mutations in Hispanic and Non-Hispanic Patients with NSCLC: Clinicopathologic Characteristics and Prognosis. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
22
|
Dawar R, Gawri K, Rodriguez E, Thammineni V, Saul E, Lima Filho JO, Dempsey N, Khan K, Torres T, Kwon D, Lopes G. P01.09 Improved Outcomes With Ramucirumab & Docetaxel in Metastatic Non-Small Cell Lung Cancer After Failure of Immunotherapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
23
|
Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol 2020; 35:824-834. [PMID: 32790003 DOI: 10.1111/jdv.16866] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Accepted: 07/28/2020] [Indexed: 12/20/2022]
Abstract
Tuberculosis is an infectious disease with a major global impact, ranked in the top 10 mortality causes worldwide. In an immunocompetent individual, the host defence mechanisms control Mycobacterium tuberculosis infection and induce the latent form of the disease. However, in the presence of diseases or therapies, which exert an immunosuppressive effect, latent tuberculosis can be re-activated. Psoriasis is an immune-mediated, inflammatory disease, and its treatment has rapidly evolved over the last few years. It has long been recognized that the tumour necrosis factor (TNF)-α inhibitors are associated with increased risk of reactivation of latent tuberculosis infection. Thus, international guidelines have been suggesting tuberculosis screening before starting the treatment with all biological agents since then. In addition, the institution of chemoprophylaxis in the presence of latent tuberculosis and the annual screening for tuberculosis thereafter have also been indicated. However, anti-tuberculosis treatments can have significant side-effects and there are currently several contraindications to their use. The risk benefit of starting anti-tuberculous treatment should be carefully weighed up. The emergence of new biological drugs for the treatment of psoriasis, such as interleukin (IL)-17 and IL-23 inhibitors, has reignited the subject of tuberculosis reactivation as it is possible that IL-17 and 23 blockade do not carry the same risk of TB reactivation as TNF-α inhibitors. Although preclinical studies have shown that cytokines IL-17 and IL-23 have a possible role against infection with M. tuberculosis, data from clinical trials and post-marketing surveillance with drugs that inhibit these cytokines appear to suggest that they are not crucial to this response. In this article, we review the available data on tuberculosis reactivation after the treatment of psoriasis with IL-17 and IL-23 inhibitors, and its possible impact on the way we currently manage latent tuberculosis infection before or after starting treatment with these new drugs.
Collapse
Affiliation(s)
- M Nogueira
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - R B Warren
- The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal.,Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
| |
Collapse
|
24
|
Martínez-Pinteño A, García-Cerro S, Mas S, Torres T, Boloc D, Rodríguez N, Lafuente A, Gassó P, Arnaiz JA, Parellada E. The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. J Psychiatr Res 2020; 126:8-18. [PMID: 32407891 DOI: 10.1016/j.jpsychires.2020.04.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 04/10/2020] [Accepted: 04/18/2020] [Indexed: 12/30/2022]
Abstract
Current antipsychotics have limited efficacy in controlling cognitive and negative symptoms of schizophrenia (SZ). Glutamatergic dysregulation has been implicated in the pathophysiology of SZ, based on the capacity of N-methyl-D-aspartate receptor (NMDAR) antagonists such as ketamine (KET) to induce SZ-like behaviors. This could be related to their putative neuropathological effect on gamma-aminobutyric (GABAergic) interneurons expressing parvalbumin (PV), which would lead to a hyperglutamatergic condition. Metabotropic glutamate receptor 2 (mGluR2) negatively modulates glutamate release and has been considered a potential clinical target for novel antipsychotics drugs. Our aim was to evaluate the efficacy of JNJ-46356479 (JNJ), a positive allosteric modulator (PAM) of the mGluR2, in reversing neuropathological and behavioral deficits induced in a postnatal KET mice model of SZ. These animals presented impaired spontaneous alternation in the Y-maze test, suggesting deficits in spatial working memory, and a decrease in social motivation and memory, assessed in both the Three-Chamber and the Five Trial Social Memory tests. Interestingly, JNJ treatment of adult mice partially reversed these deficits. Mice treated with KET also showed a reduction in PV+ in the mPFC and dentate gyrus together with an increase in c-Fos expression in this hippocampal area. Compared to the control group, mice treated with KET + JNJ showed a similar PV density and c-Fos activity pattern. Our results suggest that pharmacological treatment with a PAM of the mGluR2 such as JNJ could help improve cognitive and negative symptoms related to SZ.
Collapse
Affiliation(s)
| | - Susana García-Cerro
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Spain
| | - Sergi Mas
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
| | - Teresa Torres
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Spain
| | - Daniel Boloc
- Department of Medicine, University of Barcelona, Spain
| | - Natalia Rodríguez
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Spain
| | - Amalia Lafuente
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
| | - Patricia Gassó
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Joan Albert Arnaiz
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Clinical Pharmacology Department, Hospital Clínic de Barcelona, Spain.
| | - Eduard Parellada
- The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Department of Medicine, University of Barcelona, Spain; Barcelona Clinic Schizophrenia Unit (BCSU), Institute of Neuroscience, Hospital Clinic of Barcelona, University of Barcelona, Spain.
| |
Collapse
|
25
|
Boloc D, Rodríguez N, Torres T, García-Cerro S, Parellada M, Saiz-Ruiz J, Cuesta MJ, Bernardo M, Gassó P, Lafuente A, Mas S, Arnaiz JA. Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. Psychopharmacology (Berl) 2020; 237:2151-2159. [PMID: 32382784 DOI: 10.1007/s00213-020-05526-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 04/13/2020] [Indexed: 12/14/2022]
Abstract
INTRODUCTION We explore the transcription factors involved in the molecular mechanism of antipsychotic (AP)-induced acute extrapyramidalsymptoms (EPS) in order to identify new candidate genes for pharmacogenetic studies. METHODS Protein-protein interaction (PPI) networks previously created from three pharmacogenomic models (in vitro, animal, and peripheral blood inhumans) were used to, by means of several bioinformatic tools; identify key transcription factors (TFs) that regulate each network. Once the TFs wereidentified, SNPs disrupting the binding sites (TFBS) of these TFs in the genes of each network were selected for genotyping. Finally, SNP-basedassociations with EPS were analyzed in a sample of 356 psychiatric patients receiving AP. RESULTS Our analysis identified 33 TFs expressed in the striatum, and 125 SNPs disrupting TFBS in 50 genes of our initial networks. Two SNPs (rs938112,rs2987902) in two genes (LSMAP and ABL1) were significantly associated with AP induced EPS (p < 0.001). These SNPs disrupt TFBS regulated byPOU2F1. CONCLUSION Our results highlight the possible role of the disruption of TFBS by SNPs in the pharmacological response to AP.
Collapse
Affiliation(s)
- Daniel Boloc
- Department of Medicine, University of Barcelona, Barcelona, Spain
| | | | - Teresa Torres
- Dept. Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
| | - Susana García-Cerro
- Dept. Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
| | - Mara Parellada
- Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Madrid, Spain
| | - Jeronimo Saiz-Ruiz
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Madrid, Spain
- Hospital Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain
| | - Manuel J Cuesta
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Madrid, Spain
- Department of Psychiatry, Complejo Hospitalario de Navarra. Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - Miquel Bernardo
- Department of Medicine, University of Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Madrid, Spain
- Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Barcelona, Spain
- Spain The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Patricia Gassó
- Dept. Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
- Spain The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Amalia Lafuente
- Dept. Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Madrid, Spain
- Spain The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Sergi Mas
- Dept. Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Madrid, Spain.
- Spain The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
| | - Joan Albert Arnaiz
- Dept. Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
| |
Collapse
|
26
|
Bosma A, Spuls P, Garcia‐Doval I, Naldi L, Prieto‐Merino D, Tesch F, Apfelbacher C, Arents B, Barbarot S, Baselga E, Deleuran M, Eichenfield L, Gerbens L, Irvine A, Manca A, Mendes‐Bastos P, Middelkamp‐Hup M, Roberts A, Seneschal J, Svensson Å, Thyssen J, Torres T, Vermeulen F, Vestergaard C, Kobyletzki L, Wall D, Weidinger S, Schmit J, Flohr C. 特应性湿疹的治疗 (TREAT) 登记工作组:比较 Dupilumab 与其他全身药物治疗中度至重度湿疹安全性的方法. Br J Dermatol 2020. [DOI: 10.1111/bjd.19078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
27
|
Bosma A, Spuls P, Garcia‐Doval I, Naldi L, Prieto‐Merino D, Tesch F, Apfelbacher C, Arents B, Barbarot S, Baselga E, Deleuran M, Eichenfield L, Gerbens L, Irvine A, Manca A, Mendes‐Bastos P, Middelkamp‐Hup M, Roberts A, Seneschal J, Svensson Å, Thyssen J, Torres T, Vermeulen F, Vestergaard C, Kobyletzki L, Wall D, Weidinger S, Schmitt J, Flohr C. TREatment of ATopic eczema (TREAT) Registry Taskforce: method for comparing the safety of dupilumab with other systemic therapies for moderate‐to‐severe eczema. Br J Dermatol 2020. [DOI: 10.1111/bjd.19066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Torres T, Boloc D, Rodríguez N, Blázquez A, Plana MT, Varela E, Gassó P, Martinez-Pinteño A, Lázaro L, Arnaiz JA, Mas S. Response to fluoxetine in children and adolescents: a weighted gene co-expression network analysis of peripheral blood. Am J Transl Res 2020; 12:2028-2040. [PMID: 32509197 PMCID: PMC7269974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2019] [Accepted: 02/13/2020] [Indexed: 06/11/2023]
Abstract
The inconclusive and non-replicated results of pharmacogenetic studies of antidepressant response could be related to the lack of acknowledgement of its mechanism of action. In this scenario, gene expression studies provide and interesting framework to reveal new candidate genes for pharmacogenetic studies or peripheral biomarkers of fluoxetine response. We propose a system biology approach to analyse changes in gene expression induced by eight weeks of treatment with fluoxetine in peripheral blood. 21 naïve child and adolescents participated in the present study. Our analysis include the identification of gene co-expression modules, using Weighted Gene Co-expression Network Analysis (WGCNA), followed by protein-protein interaction (PPi) network construction coupled with functional annotation. Our results revealed two modules of co-expression genes related to fluoxetine treatment. The constructed networks from these modules were enriched for biological processes related to cellular and metabolic processes, cell communication, immune system processes, cell death, response to stimulus and neurogenesis. Some of these processes, such as immune system, replicated previous findings in the literature, whereas, neurogenesis, a mechanism proposed to be involved in fluoxetine response, had been identified for first time using peripheral tissues. In conclusion, our study identifies several biological processes in relation to fluoxetine treatment in peripheral blood, offer new candidate genes for pharmacogenetic studies and valuable markers for peripheral moderator biomarkers discovery.
Collapse
Affiliation(s)
- Teresa Torres
- Department of Clinical Foundations, Pharmacology Unit, University of BarcelonaBarcelona, Spain
| | - Daniel Boloc
- Department of Medicine, University of BarcelonaBarcelona, Spain
| | | | - Ana Blázquez
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de BarcelonaBarcelona, Spain
| | - Maria Teresa Plana
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de BarcelonaBarcelona, Spain
| | - Eva Varela
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de BarcelonaBarcelona, Spain
| | - Patricia Gassó
- Department of Clinical Foundations, Pharmacology Unit, University of BarcelonaBarcelona, Spain
- The August Pi i Sunyer Biomedical Research Institute (IDIBAPS)Barcelona, Spain
| | - Albert Martinez-Pinteño
- Department of Clinical Foundations, Pharmacology Unit, University of BarcelonaBarcelona, Spain
| | - Luisa Lázaro
- Department of Medicine, University of BarcelonaBarcelona, Spain
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de BarcelonaBarcelona, Spain
- The August Pi i Sunyer Biomedical Research Institute (IDIBAPS)Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health InstituteMadrid, Spain
| | - Joan Albert Arnaiz
- Department of Clinical Foundations, Pharmacology Unit, University of BarcelonaBarcelona, Spain
- The August Pi i Sunyer Biomedical Research Institute (IDIBAPS)Barcelona, Spain
| | - Sergi Mas
- Department of Clinical Foundations, Pharmacology Unit, University of BarcelonaBarcelona, Spain
- The August Pi i Sunyer Biomedical Research Institute (IDIBAPS)Barcelona, Spain
- Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health InstituteMadrid, Spain
| |
Collapse
|
29
|
Affiliation(s)
- M A Rodrigues
- Serviço de Dermatologia do Centro Hospitalar e Universitário do Porto, Porto, Portugal
| | - T Torres
- Serviço de Dermatologia do Centro Hospitalar e Universitário do Porto, Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Porto, Portugal
| |
Collapse
|
30
|
Bosma A, Spuls P, Garcia‐Doval I, Naldi L, Prieto‐Merino D, Tesch F, Apfelbacher C, Arents B, Barbarot S, Baselga E, Deleuran M, Eichenfield L, Gerbens L, Irvine A, Manca A, Mendes‐Bastos P, Middelkamp‐Hup M, Roberts A, Seneschal J, Svensson Å, Thyssen J, Torres T, Vermeulen F, Vestergaard C, Kobyletzki L, Wall D, Weidinger S, Schmitt J, Flohr C. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. Br J Dermatol 2019; 182:1423-1429. [DOI: 10.1111/bjd.18452] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/15/2019] [Indexed: 11/27/2022]
Affiliation(s)
- A.L. Bosma
- Amsterdam UMC, Location AMC, University of Amsterdam Department of Dermatology Amsterdam Public health, Infection and Immunity Amsterdam the Netherlands
| | - P.I. Spuls
- Amsterdam UMC, Location AMC, University of Amsterdam Department of Dermatology Amsterdam Public health, Infection and Immunity Amsterdam the Netherlands
| | - I. Garcia‐Doval
- Research Unit Academia Española de Dermatología y Venereología Madrid Spain
- Dermatology Department Complexo Hospitalario Universitario de Vigo Vigo Spain
| | - L. Naldi
- Centro Studi GISED Bergamo Italy
| | - D. Prieto‐Merino
- Applied Statistics in Medical Research Group Catholic University of Murcia (UCAM) Murcia Spain
- Faculty of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London U.K
| | - F. Tesch
- Center for Evidence‐based Healthcare Medizinische Fakultät Carl Gustav Carus, TU Dresden Dresden Germany
| | - C.J. Apfelbacher
- Institute of Epidemiology and Preventive Medicine University of Regensburg Regensburg Germany
| | - B.W.M. Arents
- Dutch Association for People with Atopic Dermatitis Nijkerk the Netherlands
| | - S. Barbarot
- Department of Dermatology CHU Nantes Nantes France
| | - E. Baselga
- Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain
| | - M. Deleuran
- Department of Dermatology Aarhus University Hospital Aarhus Denmark
| | - L.F. Eichenfield
- Department of Dermatology and Pediatrics University of California San Diego CA U.S.A
| | - L.A.A. Gerbens
- Amsterdam UMC, Location AMC, University of Amsterdam Department of Dermatology Amsterdam Public health, Infection and Immunity Amsterdam the Netherlands
| | - A.D. Irvine
- Department of Clinical Medicine Trinity College Dublin Dublin Ireland
- National Children's Research Centre Dublin Ireland
- Department of Paediatric Dermatology Our Lady's Children's Hospital Dublin Ireland
| | - A. Manca
- Centre for Health Economics University of York York U.K
| | | | - M.A. Middelkamp‐Hup
- Amsterdam UMC, Location AMC, University of Amsterdam Department of Dermatology Amsterdam Public health, Infection and Immunity Amsterdam the Netherlands
| | - A. Roberts
- Nottingham Support Group for Carers of Children with Eczema Nottingham U.K
| | - J. Seneschal
- Department of Dermatology and Pediatric Dermatology National Reference Center for Rare Skin Diseases University Hospital of Bordeaux Bordeaux France
| | - Å. Svensson
- Department of Dermatology and Venereology Skane University Hospital Malmö Sweden
| | - J.P. Thyssen
- Department of Dermatology and Allergy Herlev‐Gentofte Hospital University of Copenhagen Hellerup Denmark
| | - T. Torres
- Department of Dermatology Centro Hospitalar Universitário Porto Porto Portugal
| | - F.M. Vermeulen
- Amsterdam UMC, Location AMC, University of Amsterdam Department of Dermatology Amsterdam Public health, Infection and Immunity Amsterdam the Netherlands
| | - C. Vestergaard
- Department of Dermatology Aarhus University Hospital Aarhus Denmark
| | - L.B. Kobyletzki
- Centre for Clinical Research Lund University Malmö Sweden
- Centre for Clinical Research Örebro University Örebro Sweden
| | - D. Wall
- St James's Hospital Dublin Ireland
- Irish Skin Foundation Dublin Ireland
| | - S. Weidinger
- Department of Dermatology and Allergy University Hospital Schleswig‐Holstein Campus Kiel Kiel Germany
| | - J. Schmitt
- Center for Evidence‐based Healthcare Medizinische Fakultät Carl Gustav Carus, TU Dresden Dresden Germany
- University Allergy Center University Hospital Carl Gustav Carus Dresden Dresden Germany
| | - C. Flohr
- Unit for Population‐Based Dermatology Research St John's Institute of Dermatology Guy's & St Thomas’ NHS Foundation Trust and King's College London London U.K
| |
Collapse
|
31
|
Novick D, Torres T, Laredo F. PCN31 BURDEN OF DISEASE FOR ADVANCED BREAST CANCER IN MEXICO. Value Health Reg Issues 2019. [DOI: 10.1016/j.vhri.2019.08.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Rodríguez N, Morer A, González-Navarro EA, Serra-Pages C, Boloc D, Torres T, Martinez-Pinteño A, Mas S, Lafuente A, Gassó P, Lázaro L. Altered frequencies of Th17 and Treg cells in children and adolescents with obsessive-compulsive disorder. Brain Behav Immun 2019; 81:608-616. [PMID: 31344493 DOI: 10.1016/j.bbi.2019.07.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Revised: 07/01/2019] [Accepted: 07/20/2019] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVE Obsessive-compulsive disorder (OCD) is a debilitating neuropsychiatric disorder with an etiopathophysiology that seems to include immune alterations. Previous studies have suggested that variations in the levels of circulating T cell subpopulations may be involved in psychiatric diseases. However, the role of these cells in OCD remains unexplored. Hence, the present study aimed to examine the levels of T helper 1 (Th1), Th2, Th17 and regulatory T (Treg) cells in patients with early-onset OCD and healthy controls. METHODS The assessment was performed in 99 children and adolescents with OCD and 46 control subjects. The percentages of circulating Th1, Th2, Th17 and Treg cells were evaluated using flow cytometry. RESULTS OCD patients had significantly higher levels of Th17 cells and lower percentages of Treg cells than healthy controls (p = 0.001 and p = 0.005, respectively). Furthermore, levels of Th17 cells progressively increased with the duration (p = 0.005) and severity of OCD (p = 0.008), whereas the percentages of Treg cells significantly declined with the duration of the disorder (p = 1.8 × 10-5). CONCLUSIONS These results provide more evidence of the involvement of immune dysregulation, specifically an imbalance in the levels of circulating T helper and regulatory T cells, in the pathophysiology of early-onset OCD.
Collapse
Affiliation(s)
| | - Astrid Morer
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| | - E Azucena González-Navarro
- Immunology Service, Hospital Clinic de Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - Carles Serra-Pages
- Immunology Service, Hospital Clinic de Barcelona, Spain; Department of Biomedicine, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - Daniel Boloc
- Department of Medicine, University of Barcelona, Spain.
| | - Teresa Torres
- Department of Basic Clinical Practice, University of Barcelona, Spain.
| | | | - Sergi Mas
- Department of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| | - Amalia Lafuente
- Department of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| | - Patricia Gassó
- Department of Basic Clinical Practice, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
| | - Luisa Lázaro
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Spain; Department of Medicine, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.
| |
Collapse
|
33
|
Donnay S, Fajardo C, Fernández-García JC, Torres T, Bandrés O, Domínguez JR, Menéndez E, Serrano J, Torrejón S, López I, Pineda JJ, Muñoz J, Lucas A, Tortosa F, Moll G, Vich F. Diagnosis, treatment, and management of gestational hypothyroidism. The TIROGEST study. ACTA ACUST UNITED AC 2019; 67:36-42. [PMID: 31109823 DOI: 10.1016/j.endinu.2019.03.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2018] [Revised: 02/03/2019] [Accepted: 03/08/2019] [Indexed: 10/26/2022]
Abstract
INTRODUCTION There is no agreement on the procedures to be used for diagnosis and treatment of gestational thyroid dysfunction. Controversy still exists on the normal range of thyroid-stimulating hormone (TSH) levels and use of gestational hypothyroidism (GH) screening. The aim of this study was to assess diagnosis and treatment of thyroid dysfunction during pregnancy in a group of Spanish hospitals. STUDY DESIGN This was a retrospective, multicenter study in pregnant females with GH attending Spanish healthcare centers from March 2013 to July 2014. Variables analyzed included diagnosis criteria for GH (availability of universal screening for gestational thyroid disorders and TSH reference values (RVs) by trimester of pregnancy): risk factors for GH, iodine intake from food or supplementation, gestational age (at diagnosis/treatment) and l-thyroxine treatment. RESULTS Fourteen centers participated in the study. Universal screening was performed in only half of the centers, and only 14% had their own TSH RVs. Overall, 257 pregnant women were enrolled, 53.7% with hypothyroidism (HT) diagnosed before pregnancy (pre-GH) and 46.3% with HT diagnosed during pregnancy (intra-GH). A comparison of intra-GH and pre-GH women showed that intra-GH women made their first visit later (59.7% vs. 75.4% respectively before week 12, p=0.007) and had more frequently high TSH levels (>2.5μIU/ml) during the first trimester (94.4% vs. 67.0% respectively, p<0.001). CONCLUSIONS Our results suggest that GH may be underdiagnosed or inadequately diagnosed in most healthcare centers. These findings suggest the need of improving the current practice in Spain.
Collapse
Affiliation(s)
- Sergio Donnay
- Hospital Universitario Fundación Alcorcón, Madrid, Spain.
| | - Carmen Fajardo
- Hospital Universitario de La Ribera, Alzira, Valencia, Spain
| | | | - Teresa Torres
- Centro de Atención Primaria Antoni Creus i Querol, Terrasa, Barcelona, Spain
| | | | | | | | | | - Sara Torrejón
- Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain
| | - Irela López
- Hospital Moisès Broggi, Sant Joan Despí, Barcelona, Spain
| | | | - José Muñoz
- Centroe de Especialidades de Seo de Urgell, Spain
| | - Anna Lucas
- Hospital Universitari "Germans Trias i Pujol", Badalona, Barcelona, Spain
| | | | - Gracia Moll
- Hospital Comarcal de Inca, Inca, Mallorca, Spain
| | | |
Collapse
|
34
|
Teixeira A, Vasconcelos V, Teixeira M, Almeida V, Azevedo R, Torres T, Sousa Lobo JM, Costa PC, Almeida IF. Mechanical Properties of Topical Anti-Psoriatic Medicines: Implications for Patient Satisfaction with Treatment. AAPS PharmSciTech 2019; 20:36. [PMID: 30604084 DOI: 10.1208/s12249-018-1246-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 11/09/2018] [Indexed: 11/30/2022] Open
Abstract
Different types of topical preparations are available as anti-psoriatic medicines, semisolid formulations being the preferred dosage forms for the treatment of body lesions. The mechanical characterization of these semisolid formulations is seldom reported, although mechanical features have been recognized to play an important role in treatment acceptability and adherence. The aim of this study was to characterize the mechanical properties of semisolid topical formulations commercially available for psoriasis treatment. One complementary aim was to evaluate patient satisfaction with topical treatment and discuss the results according to the mechanical features of the dosage form. Eight ointments (O 1-8), five creams (C 1-5), one oleogel (G1), and one excipient (E1-petrolatum) were characterized for textural properties (spreadability and penetration tests) and flow behavior. Power law model was fitted to the results. A questionnaire for the assessment of satisfaction with topical medicines used for psoriasis treatment over 6 months was developed and applied to 79 psoriasis patients. All the tested formulations presented a shear-thinning behavior with power law indexes (n) lower than 1. Ointments were distinct from the other dosage forms, since they presented higher consistency coefficients (K), firmness, and adhesiveness and this was evidenced by hierarchical cluster analysis, which identified two clusters based on the mechanical properties. Cluster 1 included the ointments and petrolatum and the cluster 2 enclosed the creams and the gel. The clusters were associated with several attributes classified by patients as analyzed with Fisher's exact test. In all cases, higher satisfaction was observed for cluster 2. The knowledge obtained regarding the influence of the dosage form on the degree of satisfaction with the treatment could be helpful in supporting the selection of the dosage form in clinical practice and thus improve treatment adherence and clinical outcomes. The differences observed between the mechanical properties of the formulations studied may be also relevant to the industry, as guidance to the development of new medicines.
Collapse
|
35
|
Plana MT, Torres T, Rodríguez N, Boloc D, Gassó P, Moreno E, Lafuente A, Castro-Fornieles J, Mas S, Lazaro L. Genetic variability in the serotoninergic system and age of onset in anorexia nervosa and obsessive-compulsive disorder. Psychiatry Res 2019; 271:554-558. [PMID: 30554102 DOI: 10.1016/j.psychres.2018.12.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 11/05/2018] [Accepted: 12/03/2018] [Indexed: 12/18/2022]
Abstract
The age of onset of some psychiatric disorders may have etiopathogenic and clinical effects and may influence outcome. Following on from previous work by our group where we showed that early onset anorexia nervosa (AN) and obsessive-compulsive disorder (OCD) shared a common genetic background, the aim of the present study is to assess genetic pleiotropy related to the serotonergic system (SLC6A4, 5HTR2A, 5HTR2C, TPH2, SLC18A1), in a common phenotype such as very-early age of onset. One hundred and sixteen adolescents diagnosed with AN and 74 adolescents diagnosed with OCD participated in the present study. We confirmed the existence of a genetic overlap between OCD and AN. Specifically, we described genetic pleiotropy for age at onset across these disorders, associating two SNPs (rs6311, rs4942587) of the HTR2A with the very-early onset phenotype.
Collapse
Affiliation(s)
- Maria Teresa Plana
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, C/ Villarroel 170, E-08036 Barcelona, Spain.
| | - Teresa Torres
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
| | - Natalia Rodríguez
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
| | - Daniel Boloc
- Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Patricia Gassó
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Elena Moreno
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, C/ Villarroel 170, E-08036 Barcelona, Spain
| | - Amalia Lafuente
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Spain
| | - Josefina Castro-Fornieles
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, C/ Villarroel 170, E-08036 Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Spain
| | - Sergi Mas
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Spain
| | - Luisa Lazaro
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, C/ Villarroel 170, E-08036 Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Spain.
| |
Collapse
|
36
|
Gassó P, Blázquez A, Rodríguez N, Boloc D, Torres T, Mas S, Lafuente A, Lázaro L. Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism. J Child Adolesc Psychopharmacol 2018; 28:711-718. [PMID: 29975559 DOI: 10.1089/cap.2018.0004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Objective: Fluoxetine is an effective and well-tolerated pharmacological treatment for children and adolescents with major depressive disorder (MDD). However, a high percentage of patients do not respond. There is a substantial genetic contribution to this variable clinical outcome. Based on previous genetic results of our group and given the lack of pharmacogenetics studies of antidepressant response with a long follow-up period, we evaluated the influence of single nucleotide polymorphisms (SNPs) in genes related to the serotonergic pathway on remission and recovery in children and adolescents diagnosed with MDD after 12 months of initiating fluoxetine treatment. Methods: The assessment was performed in 46 patients. All of them were visited at least once a month during the 12-month follow-up. Psychiatrists interviewed patients and their parents to explore clinical improvement. A total of 75 genotyped SNPs in 10 candidate genes were included in the genetic association analysis with remission and recovery. Bonferroni correction for multiple testing was applied to avoid false positive results. Results: The HTR2A rs7997012 SNP was significantly associated after Bonferroni correction with clinical improvement. Particularly, the homozygotes for the major allele (GG) showed the highest percentage of remitters and the highest score reductions on the Clinical Global Impressions-Severity (CGI-S) scale. Moreover, although the results were on the border of statistical significance, the GG homozygotes also tended to experience fewer readmissions during the follow-up period Conclusions: These results provide more evidence of the involvement of genetic variants related to the serotonergic pathway in the antidepressant response. Studies with larger cohorts are needed to integrate all relevant variants into clinical predictors of antidepressant response.
Collapse
Affiliation(s)
- Patricia Gassó
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Ana Blázquez
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Natalia Rodríguez
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Barcelona, Spain
| | - Daniel Boloc
- Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Teresa Torres
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Barcelona, Spain
| | - Sergi Mas
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | - Amalia Lafuente
- Department of Basic Clinical Practice, Unit of Pharmacology, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| | - Luisa Lázaro
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
| |
Collapse
|
37
|
Vasconcelos V, Teixeira A, Almeida V, Teixeira M, Ramos S, Torres T, Sousa Lobo JM, Almeida IF. Patient preferences for attributes of topical anti-psoriatic medicines. J DERMATOL TREAT 2018; 30:659-663. [PMID: 30470146 DOI: 10.1080/09546634.2018.1544410] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Background: Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. Objective: The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. Methods: A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (PSO-TOPAP) and was applied to a total of seventy-nine patients, members of the Portuguese Association of Psoriasis (PSOPortugal) or outpatients of a dermatology unit of a central hospital. Results: Overall, attributes belonging to the formulation and application domains were greatly valued over attributes related to the container. Only a small number of patient preferences was influenced by age, gender, duration of the disease and age at first diagnosis. Limitations: Our findings need to be verified in larger and more diverse patient samples before generalization can be made. Conclusion: The insight obtained in this work can provide guidance to pharmaceutical drug product design and has also the potential to improve patient care through the acknowledgment of patient preferences in clinical practice.
Collapse
Affiliation(s)
- V Vasconcelos
- a CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde , Gandra PRD , Portugal
| | - A Teixeira
- a CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde , Gandra PRD , Portugal.,b UCIBIO- REQUIMTE, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy University of Porto , Porto , Portugal
| | - V Almeida
- a CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde , Gandra PRD , Portugal.,b UCIBIO- REQUIMTE, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy University of Porto , Porto , Portugal
| | - M Teixeira
- a CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde , Gandra PRD , Portugal
| | - S Ramos
- c ISEP, Instituto Superior de Engenharia do Porto, Politécnico do Porto , Porto , Portugal.,d CEAUL, Centro de Estatística e Aplicações da Universidade de Lisboa, Faculdade de Ciências , Campo Grande , Portugal
| | - T Torres
- e Serviço de Dermatologia, Centro Hospitalar do Porto, Hospital de Santo António , Porto , Portugal
| | - J M Sousa Lobo
- b UCIBIO- REQUIMTE, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy University of Porto , Porto , Portugal
| | - I F Almeida
- b UCIBIO- REQUIMTE, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy University of Porto , Porto , Portugal
| |
Collapse
|
38
|
Torres T. Selective Il-23 Inhibitors: The New Kids on the Block in the Treatment of Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 2018. [DOI: 10.1016/j.adengl.2018.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
39
|
Virkki K, Tervola E, Ince M, Torres T, Tkachenko NV. Comparison of electron injection and recombination on TiO 2 nanoparticles and ZnO nanorods photosensitized by phthalocyanine. R Soc Open Sci 2018; 5:180323. [PMID: 30109087 PMCID: PMC6083689 DOI: 10.1098/rsos.180323] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 06/07/2018] [Indexed: 06/08/2023]
Abstract
Titanium dioxide (TiO2) and zinc oxide (ZnO) semiconductors have similar band gap positions but TiO2 performs better as an anode material in dye-sensitized solar cell applications. We compared two electrodes made of TiO2 nanoparticles and ZnO nanorods sensitized by an aggregation-protected phthalocyanine derivative using ultrafast transient absorption spectroscopy. In agreement with previous studies, the primary electron injection is two times faster on TiO2, but contrary to the previous results the charge recombination is slower on ZnO. The latter could be due to morphology differences and the ability of the injected electrons to travel much further from the sensitizer cation in ZnO nanorods.
Collapse
Affiliation(s)
- K. Virkki
- Laboratory of Chemistry and Bioengineering, Tampere University of Technology, PO Box 541, 33101 Tampere, Finland
| | - E. Tervola
- Laboratory of Chemistry and Bioengineering, Tampere University of Technology, PO Box 541, 33101 Tampere, Finland
| | - M. Ince
- Departamento de Química Orgánica, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
- Advanced Technology Research and Application Center, Mersin University, Ciftlikkoy Campus, 33343 Mersin, Turkey
- Department of Energy Systems Engineering, Faculty of Tarsus Technology, Mersin University, 33480 Mersin, Turkey
| | - T. Torres
- Departamento de Química Orgánica, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain
- Institute for Advanced Research in Chemical Sciences (IAdChem), Universidad Autónoma de Madrid, 28049 Madrid, Spain
- IMDEA Nanociencia, C/Faraday, 9, Cantoblanco, 28049 Madrid, Spain
| | - N. V. Tkachenko
- Laboratory of Chemistry and Bioengineering, Tampere University of Technology, PO Box 541, 33101 Tampere, Finland
| |
Collapse
|
40
|
Ponzo J, Berra S, Giraldo-Osorio A, Pasarín MI, Leyns C, Álvarez CV, Soto C, Molina D, Fuentes-García A, Hauser L, Magne J, Chicaiza V, Torres T, Mora FG, Terra A, Harzheim E, Ferre P, Borja-Aburto V, Fuentes M. Armonización iberoamericana de los instrumentos PCAT para la evaluación del primer nivel de atención. Rev Panam Salud Publica 2018; 42:e80. [PMID: 31093108 PMCID: PMC6386131 DOI: 10.26633/rpsp.2018.80] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- Jacqueline Ponzo
- Universidad de la República, Facultad de Medicina, Montevideo, Uruguay
| | - Silvina Berra
- Universidad Nacional de Córdoba, Escuela de Salud Pública, Córdoba, Argentina
| | | | | | - Christine Leyns
- Asociación Interdisciplinaria de Atención Primaria de Salud, Bolivia
| | | | - Carlos Soto
- Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | | | - Lisiane Hauser
- Universidade Federal do Rio Grande do Sul. Faculdade de Medicina. Programa de Pos-Graduação em Epidemiologia, Porto Alegre, RS, Brasil
| | - Jenny Magne
- Asociación Interdisciplinaria de Atención Primaria de Salud, Bolivia
| | | | - Teresa Torres
- Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | - Agustina Terra
- Universidad Nacional de Córdoba, Escuela de Salud Pública, Córdoba, Argentina
| | - Erno Harzheim
- Secretaria Municipal de Saúde de Porto Alegre, Porto Alegre, RS. Brasil
| | | | | | - Mauricio Fuentes
- Universidad de Chile, Escuela de Salud Pública, Santiago Chile, Chile
| |
Collapse
|
41
|
Queirós N, Torres T. HIV-associated psoriasis. Actas Dermo-Sifiliográficas (English Edition) 2018. [DOI: 10.1016/j.adengl.2018.02.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
42
|
Pereira R, Raposo I, Nery F, Torres T. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases. Actas Dermo-Sifiliográficas (English Edition) 2018. [DOI: 10.1016/j.adengl.2017.07.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
43
|
Pereira R, Raposo I, Nery F, Torres T. Risk of hepatitis B virus reactivation in patients treated with anti-TNFα agents for immune-mediated inflammatory diseases. Actas Dermo-Sifiliográficas 2018; 109:285-287. [DOI: 10.1016/j.ad.2017.07.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 06/06/2017] [Accepted: 07/16/2017] [Indexed: 10/18/2022] Open
|
44
|
Ferreira S, Torres T. Dupilumab for the Treatment of Atopic Dermatitis. Actas Dermosifiliogr (Engl Ed) 2018; 109:230-240. [PMID: 29422431 DOI: 10.1016/j.ad.2017.10.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Revised: 10/25/2017] [Accepted: 10/25/2017] [Indexed: 12/12/2022] Open
Abstract
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. AD usually starts in early childhood and has a heterogeneous course. Emerging evidence suggests that IL-4 and IL-13 are key cytokines in the immunopathogenesis of AD. Dupilumab is a monoclonal antibody directed against IL-4 receptor α subunit, that blocks both IL-4 and IL-13 signaling. Data from Phase I-III studies revealed that dupilumab, administered as monotherapy or with topical corticosteroids, is effective and well tolerated in the treatment of adult patients with moderate-to-severe AD. A large proportion of patients receiving dupilumab had significant improvements in multiple efficacy indexes, including Eczema Area and Severity Index, Investigator's Global Assessment and SCORing Atopic Dermatitis scores. These results introduce a new era of targeted therapies in the management of AD.
Collapse
Affiliation(s)
- S Ferreira
- Unidad de Dermatología, Centro Hospitalar Universitário do Porto, Oporto, Portugal
| | - T Torres
- Unidad de Dermatología, Centro Hospitalar Universitário do Porto, Oporto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Oporto, Portugal.
| |
Collapse
|
45
|
Abstract
Human immunodeficiency virus (HIV) prevalence is increasing worldwide as people on antiretroviral therapy are living longer. These patients are often susceptible to debilitating inflammatory disorders that are frequently refractory to standard treatment. Psoriasis is a systemic inflammatory disorder, associated with both physical and psychological burden, and can be the presenting feature of HIV infection. In this population, psoriasis tends to be more severe, to have atypical presentations and higher failure rates with the usual prescribed treatments. Management of moderate and severe HIV-associated psoriasis is challenging. Systemic conventional and biologic agents may be considered, but patients should be carefully followed up for potential adverse events, like opportunist infections, and regular monitoring of CD4 counts and HIV viral loads.
Collapse
Affiliation(s)
- N Queirós
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
| | - T Torres
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal; Unidad de Dermatología, Centro Hospitalar e Universitário do Porto, Porto, Portugal.
| |
Collapse
|
46
|
Rodríguez N, Morer A, González-Navarro EA, Serra-Pages C, Boloc D, Torres T, García-Cerro S, Mas S, Gassó P, Lázaro L. Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. J Neuroinflammation 2017; 14:261. [PMID: 29284508 PMCID: PMC5746006 DOI: 10.1186/s12974-017-1042-z] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Accepted: 12/13/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Although the exact etiology of obsessive-compulsive disorder (OCD) is unknown, there is growing evidence of a role for immune dysregulation in the pathophysiology of the disease, especially in the innate immune system including the microglia. To test this hypothesis, we studied inflammatory markers in monocytes from pediatric patients with OCD and from healthy controls. METHODS We determined the percentages of total monocytes, CD16+ monocytes, and classical (CD14highCD16-), intermediate (CD14highCD16low), and non-classical (CD14lowCD16high) monocyte subsets in 102 patients with early-onset OCD and in 47 healthy controls. Moreover, proinflammatory cytokine production (GM-CSF, IL-1β, IL-6, IL-8, and TNF-α) was measured by multiplex Luminex analysis in isolated monocyte cultures, in basal conditions, after exposure to lipopolysaccharide (LPS) to stimulate immune response or after exposure to LPS and the immunosuppressant dexamethasone. RESULTS OCD patients had significantly higher percentages of total monocytes and CD16+ monocytes than healthy controls, mainly due to an increase in the intermediate subset but also in the non-classical monocytes. Monocytes from OCD patients released higher amounts of GM-CSF, IL-1β, IL-6, IL-8, and TNF-α than healthy controls after exposure to LPS. However, there were no significant differences in basal cytokine production or the sensitivity of monocytes to dexamethasone treatment between both groups. Based on monocyte subset distribution and cytokine production after LPS stimulation, patients receiving psychoactive medications seem to have an intermediate inflammatory profile, that is, lower than non-medicated OCD individuals and higher than healthy controls. CONCLUSIONS These results strongly support the involvement of an enhanced proinflammatory innate immune response in the etiopathogenesis of early-onset OCD.
Collapse
Affiliation(s)
- Natalia Rodríguez
- Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain
| | - Astrid Morer
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
| | - E Azucena González-Navarro
- Immunology Service, Hospital Clinic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Carles Serra-Pages
- Immunology Service, Hospital Clinic de Barcelona, Barcelona, Spain.,Department of Biomedicine, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Daniel Boloc
- Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Teresa Torres
- Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain
| | - Susana García-Cerro
- Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain
| | - Sergi Mas
- Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
| | - Patricia Gassó
- Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Luisa Lázaro
- Department of Child and Adolescent Psychiatry and Psychology, Institute of Neurosciences, Hospital Clinic de Barcelona, Barcelona, Spain. .,Department of Medicine, University of Barcelona, Barcelona, Spain. .,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. .,Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
| |
Collapse
|
47
|
Azevedo A, Torres T. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 2017. [DOI: 10.1016/j.adengl.2016.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
48
|
Azevedo A, Torres T. Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. Actas Dermo-Sifiliográficas 2017; 108:305-314. [DOI: 10.1016/j.ad.2016.09.021] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2016] [Revised: 09/14/2016] [Accepted: 09/18/2016] [Indexed: 01/18/2023] Open
|
49
|
Mota F, Selores M, Torres T. Importance of educational sessions on cardiometabolic comorbidities. Awareness among psoriasis patients. Actas Dermo-Sifiliográficas (English Edition) 2016. [DOI: 10.1016/j.adengl.2015.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
50
|
Torres T, Romanelli M, Chiricozzi A. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs 2016; 25:751-4. [DOI: 10.1080/13543784.2016.1187130] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|